Cellectis (CLLS) Reports Q4 EPS of EUR0.59
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cellectis Reports Fourth Quarter and Full Year 2015 Financial Results
March 14, 2016 5:19 PM EDT- On track with submission of UCART19 Clinical Trial Application; Application Filed with MHRA (UK)
- Encouraging data from the First-in-Human compassionate use of UCART19
- Early opt-in by Servier into UCART19; amendment with improved economics
- Successful production of UCART19 batches in GMP conditions; the first
off-the-shelf UCART product candidate
- On track with GMP UCART123 production; IND filing expected later in 2016
- FY2015 Revenues and other income of $61.4 million (56.4 million), with an adjusted net income of $10.3 million (9.5 million)
- Strong... More
